Caribou Biosciences, the off-the-shelf cell therapy outfit that spun out of Nobel Laureate Jennifer Doudna’s lab in 2011, is ...

TCGX is expanding its operations to Asia in connection with the fund, opening offices in Shanghai and Hong Kong. Dandan Dong, ...

Stryker veteran Spencer Stiles will take up the chief executive role as its former CEO Kevin Lobo will move into the ...

Cadrenal Therapeutics, a heart-focused biotech that recently reached an agreement with the FDA on the design of a pivotal ...

MimiVax's cancer vaccine missed the primary endpoint of a phase 2 study in patients with newly diagnosed glioblastoma, although the biotech claimed it can still see a path forward for the candidate | ...

Matchpoint Therapeutics has aced its series B round, serving up $150 million to advance the Sanofi-backed biotech’s pipeline ...

The U.S. Department of Health and Human Services announced the launching of a new program aimed to remove barriers that slow clinical development and transform how clinical trials are designed and ...

Atsena expects to complete enrollment in the third part of the Lighthouse study next year. (den-belitsky/iStock/ Plus) Atsena Therapeutics has reported evidence of efficacy in a clinical trial of an ...

Big Pharma-backed Nuvig Therapeutics has halted one of two trials for its sole clinical asset after determining the program ...

Genentech is paying Alector $100 million upfront for exclusive rights to a preclinical drug candidate that targets a driver ...

Eli Lilly-backed TRex Bio is aiming for a $111.3 million IPO, while hypertension-focused Retension Pharmaceuticals hopes for ...

Kairos Pharma is moving prostate cancer prospect ENV-105 into an earlier line of treatment in response to midphase survival ...